Screening for Cushing’s syndrome: Is it worthwhile?

Pituitary

Volumn 18, Issue 2, 2015, Pages 201-205

  Shimon, Ilan ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adrenal; Cortisol; Cushing s syndrome; Dexamethasone suppression test; Screening

Indexed keywords

DEXAMETHASONE;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; COMORBIDITY; ENDOCRINE FUNCTION TEST; HUMAN; MASS SCREENING; PATIENT SELECTION; PITUITARY ACTH HYPERSECRETION; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADRENAL CORTEX FUNCTION TESTS; COMORBIDITY; DEXAMETHASONE; HUMANS; MASS SCREENING; PATIENT SELECTION; PITUITARY ACTH HYPERSECRETION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84939996333     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-015-0634-9     Document Type: Review

References (31)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617
2. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540
3. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Alì A, Giovagnetti M, Opocher G, Angeli A (2000) A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J Clin Endocrinol Metab 85:637–644
4. Morelli V, Reimondo G, Giordano R, Della Casa S, Policola C, Palmieri S, Salcuni AS, Dolci A, Mendola M, Arosio M, Ambrosi B, Scillitani A, Ghigo E, Beck-Peccoz P, Terzolo M, Chiodini I (2014) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99:827–834
5. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L (2002) Overnight dexamethasone suppression test: a reliable screen for Cushing’s syndrome in the obese. Obes Res 10:1217–1221
6. Tiryakioglu O, Ugurlu S, Yalin S, Yirmibescik S, Caglar E, Yetkin DO, Kadioglu P (2010) Screening for Cushing’s syndrome in obese patients. Clinics (Sao Paulo) 65:9–13
7. Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK (2009) Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab 94:3857–3864
8. Fierabracci P, Pinchera A, Martinelli S, Scartabelli G, Salvetti G, Giannetti M, Pucci A, Galli G, Ricco I, Querci G, Rago T, Di Salvo C, Anselmino M, Vitti P, Santini F (2011) Prevalence of endocrine diseases in morbidly obese patients scheduled for bariatric surgery: beyond diabetes. Obes Surg 21:54–60
9. Janković D, Wolf P, Anderwald CH, Winhofer Y, Promintzer-Schifferl M, Hofer A, Langer F, Prager G, Ludvik B, Gessl A, Luger A, Krebs M (2012) Prevalence of endocrine disorders in morbidly obese patients and the effects of bariatric surgery on endocrine and metabolic parameters. Obes Surg 22:62–69
10. Leibowitz G, Tsur A, Chayen SD, Salameh M, Raz I, Cerasi E, Gross DJ (1996) Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 44:717–722
11. Chiodini I, Torlontano M, Scillitani A, Arosio M, Bacci S, Di Lembo S, Epaminonda P, Augello G, Enrini R, Ambrosi B, Adda G, Trischitta V (2005) Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case–control study in hospitalized patients. Eur J Endocrinol 153:837–844
12. Contreras LN, Cardoso E, Lozano MP, Pozzo J, Pagano P, Claus-Hermbeg H (2000) Detection of preclinical Cushing’s syndrome in overweight type 2 diabetic patients. Medicina (B Aires) 60:326–330
13. Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, Gin H, Roger P, Tabarin A (2003) Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab 88:5808–5813
14. Reimondo G, Pia A, Allasino B, Tassone F, Bovio S, Borretta G, Angeli A, Terzolo M (2007) Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol (Oxf) 67:225–229
15. Mullan K, Black N, Thiraviaraj A, Bell PM, Burgess C, Hunter SJ, McCance DR, Leslie H, Sheridan B, Atkinson AB (2010) Is there value in routine screening for Cushing’s syndrome in patients with diabetes? J Clin Endocrinol Metab 95:2262–2265
16. Gagliardi L, Chapman IM, O’Loughlin P, Torpy DJ (2010) Screening for subclinical Cushing’s syndrome in type 2 diabetes mellitus: low false-positive rates with nocturnal salivary cortisol. Horm Metab Res 42:280–284
17. Terzolo M, Reimondo G, Chiodini I et al (2012) Screening of Cushing’s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J Clin Endocrinol Metab 97:3467–3475
18. Anderson GH Jr, Blakeman N, Streeten DH (1994) The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12:609–615
19. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004) Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27:193–202
20. Martins LC, Conceição FL, Muxfeldt ES, Salles GF (2012) Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens 30:967–973
21. Trifanescu R, Carsote M, Caragheorgheopol A, Hortopan D, Dumitrascu A, Dobrescu M, Poiana C (2013) Screening for secondary endocrine hypertension in young patients. Maedica (Buchar) 8:108–115
22. van der Eerden AW, den Heijer M, Oyen WJ, Hermus AR (2007) Cushing’s syndrome and bone mineral density: lowest Z scores in young patients. Neth J Med 65:137–141
23. Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing’s syndrome and bone. Pituitary 7:249–252
24. Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, Santini SA, Guglielmi G, Carnevale V, Scillitani A (2007) Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 147:541–548
25. Kann P, Laudes M, Piepkorn B, Heintz A, Beyer J (2001) Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. Clin Rheumatol 20:25–29
26. Tsvetov G, Shimon I, Benbassat C (2007) Adrenal incidentaloma: clinical characteristics and comparison between patients with and without extra adrenal malignancy. J Endocrinol Invest 30:647–652
27. Comlekci A, Yener S, Ertilav S, Secil M, Akinci B, Demir T, Kebapcilar L, Bayraktar F, Yesil S, Eraslan S (2010) Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 37:40–46
28. Olsen H, Nordenström E, Bergenfelz A, Nyman U, Valdemarsson S, Palmqvist E (2012) Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42:164–173
29. Kim J, Bae KH, Choi YK, Jeong JY, Park KG, Kim JG, Lee IK (2013) Clinical characteristics for 348 patients with adrenal incidentaloma. Endocrinol Metab (Seoul) 28:20–25
30. Cho YY, Suh S, Joung JY, Jeong H, Je D, Yoo H, Park TK, Min YK, Kim KW, Kim JH (2013) Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas. Korean J Intern Med 28:557–564
31. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, Reimondo G, Pia A, Toscano V, Zini M, Borretta G, Papini E, Garofalo P, Allolio B, Dupas B, Mantero F, Tabarin A, Italian Association of Clinical Endocrinologists (2011) AME position statement on adrenal incidentaloma. Eur J Endocrinol 164:851–870